Similar articles

• Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids.

  Boyer JD, Cohen AD, Ugen KE, Edgeworth RL, Bennett M, Shah A, Schumann K, Nath B, Javadian A, Bagarazzi ML, Kim J, Weiner DB. Boyer JD, et al. AIDS. 2000 Jul 28;14(11):1515-22. doi: 10.1097/00002030-200007280-00007. AIDS. 2000. PMID: 10983638
• Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.

  Garzón MR, Berraondo P, Crettaz J, Ochoa L, Vera M, Lasarte JJ, Vales A, Van Rooijen N, Ruiz J, Prieto J, Zulueta J, González-Aseguinolaza G. Garzón MR, et al. Vaccine. 2005 Feb 3;23(11):1384-92. doi: 10.1016/j.vaccine.2004.09.009. Vaccine. 2005. PMID: 15661387
• DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8⁺ T-Cell Responses by Interleukin-12 Plasmid DNA.

  Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N; NIAID HIV Vaccine Trials Network. Li SS, et al. Clin Vaccine Immunol. 2017 Nov 6;24(11):e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov. Clin Vaccine Immunol. 2017. PMID: 28931520 Free PMC article. Clinical Trial.
• Nucleic acid-based vaccines as an approach to immunization against human immunodeficiency virus type-1.

  Bagarazzi ML, Boyer JD, Ayyavoo V, Weiner DB. Bagarazzi ML, et al. Curr Top Microbiol Immunol. 1998;226:107-43. doi: 10.1007/978-3-642-80475-5_8. Curr Top Microbiol Immunol. 1998. PMID: 9479839 Review. No abstract available.
• The HIV vaccine pipeline, from preclinical to phase III.

  Schultz AM, Bradac JA. Schultz AM, et al. AIDS. 2001;15 Suppl 5:S147-58. doi: 10.1097/00002030-200100005-00018. AIDS. 2001. PMID: 11816163 Review. No abstract available.